Skip to content

Aqualase Versus Torsional ip. A Study on Endothelial Cells, Corneal Edema and Corneal Sensitivity

Liquefaction Versus Torsional ip. A Comparative Study on Endothelial Cells, Corneal Edema and Corneal Sensitivity

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01480557
Enrollment
75
Registered
2011-11-29
Start date
2011-04-30
Completion date
2011-11-30
Last updated
2017-01-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cataract

Keywords

cataract, phacoemulsification, liquefaction, torsional ip, endothelial cell count, central corneal edema, central corneal sensitivity

Brief summary

Objective of this study is the comparative assessment of the impact of torsional and liquefaction technologies on endothelial cells (ECC), corneal edema (CCT) and corneal sensitivity (CCS) in a sample of cataract patients. Participants were recruited from the Cataract Service of the UHA in a consecutive-if-eligible basis. Eligibility criteria included diagnosis of senile cataract with stage 2 nuclear opalescence according to the Lens Opacities Classification System III (LOCS-3) grading scale \[10\]. By means of a custom computer randomization program all participants randomly populated two study groups according to the cataract-extraction technology used: a) Torsional group (TG) and b) Liquefaction group (LG).

Interventions

PROCEDUREliquefaction

Cataract extraction surgery type

PROCEDURETorsional ip

A type cataract surgery using torsional ip technology

Sponsors

Democritus University of Thrace
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
55 Years to 95 Years
Healthy volunteers
No

Inclusion criteria

* Diagnosis of senile cataract with stage 2 nuclear opalescence according to the Lens Opacities Classification System III (LOCS-3) grading scale

Exclusion criteria

* Endothelial cell count less than 1900, * glaucoma, * IOP-lowering medications, * former incisional surgery, * former diagnosis of corneal disease, * diabetes or autoimmune diseases

Design outcomes

Primary

MeasureTime frame
Endothelial cell count (ECC)1 month postoperatively

Secondary

MeasureTime frame
Uncorrected visual acuity (UVA)1 month postoperatively
Central corneal thickness (CCT)1 month postoperatively
Central Corneal Sensitivity (CCS)1 month postoperatively

Countries

Greece

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026